Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foster in severe COPD
NCT00929851Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2009
- Primary completion
- Mar 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclometasone dipropionate + formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Rate of COPD exacerbations at 48 weeks and Forced Expiratory Volume in 1 second at 48 weeks. Started Oct 2009; status: completed.
02
Drugs
beclometasone dipropionate + formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00929851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00929851.